Recent PHVS News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/11/2024 10:52:06 AM
- Pharvaris Announces Annual Meeting of Shareholders • GlobeNewswire Inc. • 06/11/2024 10:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:05:02 PM
- Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses • GlobeNewswire Inc. • 06/04/2024 10:50:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/24/2024 09:04:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2024 09:54:50 PM
- Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses • GlobeNewswire Inc. • 05/13/2024 10:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 08:11:03 PM
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:10:00 PM
- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/10/2024 08:10:00 PM
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer • GlobeNewswire Inc. • 04/10/2024 08:08:00 PM
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference • GlobeNewswire Inc. • 04/04/2024 10:50:00 AM
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses • GlobeNewswire Inc. • 03/18/2024 10:50:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 05:51:18 PM
- Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/06/2024 09:40:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 09:15:02 PM
- Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses • GlobeNewswire Inc. • 03/06/2024 11:50:00 AM
- Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 • GlobeNewswire Inc. • 03/05/2024 11:50:00 AM
- Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting • GlobeNewswire Inc. • 02/22/2024 11:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/16/2024 11:51:04 AM
- Pharvaris Announces Extraordinary Meeting of Shareholders • GlobeNewswire Inc. • 02/16/2024 11:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 09:01:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:46:17 PM
- Pharvaris to Present at the WSAAI Annual Meeting 2024 • GlobeNewswire Inc. • 01/26/2024 11:50:00 AM
- Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant • Dow Jones News • 01/22/2024 12:35:00 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM